Drug Shortage Report for SODIUM ACETATE INJECTION, USP

Last updated on 2021-02-10 History
Report ID 131721
Drug Identification Number 02139529
Brand name SODIUM ACETATE INJECTION, USP
Common or Proper name Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) SODIUM ACETATE
Strength(s) 328MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 100 mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2021-01-06
Actual start date
Estimated end date Unknown
Actual end date 2021-02-09
Shortage status Resolved
Updated date 2021-02-10
Company comments Fresenius Kabi Canada Ltd. is pleased to advise that our Sodium Acetate Injection will be removed off allocation effective today, Tuesday, February 9, 2021. The product will be available to all customers without restrictions.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v7 2021-02-10 English Compare
v6 2021-02-09 French Compare
v5 2021-02-09 English Compare
v4 2021-01-15 French Compare
v3 2021-01-15 English Compare
v2 2021-01-15 French Compare
v1 2021-01-15 English Compare

Showing 1 to 7 of 7